These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1058832)

  • 41. Neuroectoderm-associated antigens on Ewing's sarcoma cell lines.
    Lipinski M; Braham K; Philip I; Wiels J; Philip T; Goridis C; Lenoir GM; Tursz T
    Cancer Res; 1987 Jan; 47(1):183-7. PubMed ID: 3024814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells.
    Lollini PL; Landuzzi L; Frabetti F; Rossi I; Nicoletti G; Scotlandi K; Serra M; Baldini N; De Giovanni C; Nanni P
    Clin Cancer Res; 1998 Aug; 4(8):1843-9. PubMed ID: 9717810
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ewing's sarcoma: new approaches to histogenesis and molecular plasticity.
    Rettig WJ; Garin-Chesa P; Huvos AG
    Lab Invest; 1992 Feb; 66(2):133-7. PubMed ID: 1735951
    [No Abstract]   [Full Text] [Related]  

  • 44. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
    Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
    Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The concept of immunotherapy of human sarcomas: the need for an in vitro monitoring assay.
    Sinkovics JG; Campos LT; Kay HD; Loh KK; Cabiness JR; Ervin F
    Ann Clin Lab Sci; 1973; 3(6):414-23. PubMed ID: 4796444
    [No Abstract]   [Full Text] [Related]  

  • 46. Workshop in human tumor immunology.
    Oettgen HF; Bean MA; Klein G
    Cancer Res; 1972 Dec; 32(12):2845-53. PubMed ID: 4345410
    [No Abstract]   [Full Text] [Related]  

  • 47. Cytotoxic activity of lymphocytes. 3. Standardization of measurement of cell-mediated lysis.
    Lucas ZJ; Walker SM
    J Immunol; 1974 Jul; 113(1):209-24. PubMed ID: 4598888
    [No Abstract]   [Full Text] [Related]  

  • 48. [Immunological study in carcinogenesis. Distribution of tissue incompatibility antigens (system HL-A) in oncological patients].
    Govallo VI; Shelepina TA
    Vopr Onkol; 1975; 21(9):13-9. PubMed ID: 1059274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cell-mediated cytotoxicity for bladder carcinoma: evaluation of a workshop.
    Bean MA; Bloom BR; Herberman RB; Old LJ; Oettgen HF; Klein G; Terry WD
    Cancer Res; 1975 Oct; 35(10):2902-13. PubMed ID: 1157057
    [No Abstract]   [Full Text] [Related]  

  • 50. Standardization of microcytotoxicity assay for cell-mediated immunity.
    O'Toole C
    Natl Cancer Inst Monogr; 1973 Jun; 37():19-24. PubMed ID: 4713781
    [No Abstract]   [Full Text] [Related]  

  • 51. Bone induction by Ewing's sarcoma. Transplantation into athymic nude mice.
    Bauer FC; Mirra JM; Urist MR
    Arch Pathol Lab Med; 1981 Jun; 105(6):322-4. PubMed ID: 6894528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transfer of in vitro cytotoxicity against osteogenic sarcoma cells.
    Sutherland CM; Krementz ET; Hornung MO; Carter RD; Holmes J
    Surgery; 1976 Jun; 79(6):682-5. PubMed ID: 1064179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Studies on specificity of cell-mediated immunity to human tumors.
    Takasugi M; Mickey MR; Terasaki PI
    J Natl Cancer Inst; 1974 Dec; 53(6):1527-38. PubMed ID: 4140237
    [No Abstract]   [Full Text] [Related]  

  • 54. beta-Adrenergic receptors in pediatric tumors: uncoupled beta 1-adrenergic receptor in Ewing's sarcoma.
    Whitsett JA; Burdsall J; Workman L; Hollinger B; Neely J
    J Natl Cancer Inst; 1983 Oct; 71(4):779-86. PubMed ID: 6312152
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The monoclonal HBA-71 antibody modulates proliferation of thymocytes and Ewing's sarcoma cells by interfering with the action of insulin-like growth factor I.
    Hamilton G; Mallinger R; Hofbauer S; Havel M
    Thymus; 1991 Aug; 18(1):33-41. PubMed ID: 1656551
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Specific inhibition of sarcoma-specific cellular immunity by sera from patients with growing sarcomas.
    Cohen AM; Ketcham AS; Morton DL
    Int J Cancer; 1973 Mar; 11(2):273-9. PubMed ID: 4524527
    [No Abstract]   [Full Text] [Related]  

  • 57. [Immunology of osteogenic sarcoma].
    Skurzak H; Rochowska MS
    Nowotwory; 1976; Suppl():21-31. PubMed ID: 1071177
    [No Abstract]   [Full Text] [Related]  

  • 58. The specificity of the microcytotoxicity assay for cell-mediated immunity in human bladder cancer.
    Vilien M; Wolf H
    J Urol; 1978 Mar; 119(3):338-42. PubMed ID: 273706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The host immune response in human osteosarcoma.
    McMaster JH; Ferguson RJ; Weinert CR
    Clin Orthop Relat Res; 1975 Sep; (111):76-82. PubMed ID: 1057466
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 'Nonspecific' blocking of human ovarian carcinoma-associated cellular cytotoxicity in vitro.
    Saksela E; Penttinen K; Pyrhönen S
    Scand J Immunol; 1974; 3(6):781-8. PubMed ID: 4376262
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.